Effect of lisinopril and atenolol on aortic stiffness in patients on hemodialysis
- PMID: 25784174
- PMCID: PMC4386263
- DOI: 10.2215/CJN.09981014
Effect of lisinopril and atenolol on aortic stiffness in patients on hemodialysis
Abstract
Background and objectives: Whether improvements in arterial compliance with BP lowering are because of BP reduction alone or if pleiotropic effects of antihypertensive agents contribute remains unclear. It was hypothesized that, among patients on hemodialysis, compared with a β-blocker (atenolol), a lisinopril-based therapy will better reduce arterial stiffness.
Design, setting, participants, & measurements: Among 200 participants of the Hypertension in Hemodialysis Patients Treated with Atenolol or Lisinopril Trial, 179 patients with valid assessment of aortic pulse wave velocity at baseline (89 patients randomly assigned to open-label lisinopril and 90 patients randomly assigned to atenolol three times a week after dialysis) were included in the secondary analysis. Among them, 109 patients had a valid pulse wave velocity measurement at 6 months. Monthly measured home BP was targeted to <140/90 mmHg by addition of antihypertensive drugs and dry weight adjustment. The difference between drugs in percentage change of aortic pulse wave velocity from baseline to 6 months was analyzed.
Results: Contrary to the hypothesis, atenolol-based treatment induced greater reduction in aortic pulse wave velocity relative to lisinopril (between drug difference, 14.8%; 95% confidence interval, 1.5% to 28.5%; P=0.03). Reduction in 44-hour ambulatory systolic and diastolic BP was no different between groups (median [25th, 75th percentile]; atenolol: -21.5 [-37.7, -7.6] versus lisinopril: -15.8 [-28.8, -1.5] mmHg; P=0.27 for systolic BP; -14.1 [-22.6, -5.3] versus -10.9 [-18.4, -0.9] mmHg, respectively; P=0.30 for diastolic BP). Between-drug difference in change of aortic pulse wave velocity persisted after adjustments for age, sex, race, other cardiovascular risk factors, and baseline ambulatory systolic BP but disappeared after adjustment for change in ambulatory systolic BP (11.8%; 95% confidence interval, -2.3% to 25.9%; P=0.10).
Conclusions: Among patients on dialysis, atenolol was superior in improving arterial stiffness. However, differences between atenolol and lisinopril in improving aortic stiffness among patients on hemodialysis may be explained by BP-lowering effects of drugs.
Keywords: aortic stiffness; hemodialysis; hypertension.
Copyright © 2015 by the American Society of Nephrology.
Comment in
-
Reducing arterial stiffness in CKD: revising the paradigms.Clin J Am Soc Nephrol. 2015 Apr 7;10(4):547-50. doi: 10.2215/CJN.01900215. Epub 2015 Mar 17. Clin J Am Soc Nephrol. 2015. PMID: 25784173 Free PMC article. No abstract available.
-
Cardiovascular disease: Questioning the effect of β-blockers on vascular stiffness.Nat Rev Nephrol. 2015 Aug;11(8):447-8. doi: 10.1038/nrneph.2015.72. Epub 2015 May 5. Nat Rev Nephrol. 2015. PMID: 25941061 No abstract available.
References
-
- Briet M, Boutouyrie P, Laurent S, London GM: Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int 82: 388–400, 2012 - PubMed
-
- Taal MW: Arterial stiffness in chronic kidney disease: An update. Curr Opin Nephrol Hypertens 23: 169–173, 2014 - PubMed
-
- Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99: 2434–2439, 1999 - PubMed
-
- Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 103: 987–992, 2001 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
